Clinical Investigation in Tumor Immunotherapy

描述(由申请人提供)：本K24职业发展奖将 请允许我继续努力将肿瘤免疫学从 实验室进入临床，提高成人实体瘤的治疗水平。这些 将努力将基于免疫的治疗应用于泌尿生殖系癌症 (尤其是前列腺癌)和黑色素瘤。审判将以斯特朗为基础 科学原理，需要与实验室科学家合作， 需要适当的患者基础，并将实验室和 除了标准的临床终点外，还有免疫终点。这个 临床研究计划将针对三个主要目标： 1.开发和测试前列腺癌的免疫治疗方法； 2.继续研究黑色素瘤生物学及发展新的治疗方法 对这种疾病。有待测试的治疗方法可能超越单纯基于免疫的治疗 方法，并将包括各级的积极参与(机构、 多机构、大型合作小组)的试验设计和 实施；以及3.继续努力使细胞因子工作组 (CWG)成为NCI资助的肿瘤免疫治疗合作组织 快速、创造性地测试更复杂的面向免疫的机制 方法主要是在第二阶段试验中。浅谈临床入门带教 调查人员是K24的关键组成部分，将专注于 将初级教员和/或血液学/肿瘤学研究员纳入以下几个项目之一 有明确职责和教育计划的培训领域。 这些包括：1.强调临床前的肿瘤免疫治疗计划， 实验室工作，将免疫监测纳入临床试验 设计、方案准备和实施；2.泌尿生殖系统(GU) 以前列腺癌免疫治疗为重点的癌症多学科计划； 和3.担任临床研究科主任 血液学/肿瘤学介绍临床试验研究 包括对教师专业知识的概述以及如何启动临床 与其中一名教员进行调查。此外，我将扮演一个 他们的临床研究顾问。通过联合我的努力来合并 实验室努力和免疫学终点与强大的临床试验 设计，我相信临床研究可以更好地推动肿瘤免疫治疗 以更合理的方式向前推进。

DESCRIPTION (provided by applicant): This K24 Career Development Award will allow me to continue my efforts to "translate" tumor immunology from the laboratory into the clinic to improve therapy of adult solid tumors. These efforts will apply immune-based treatments to genitourinary cancers (especially prostate) and melanoma. The trials will be based on strong scientific rationale, require collaborations with laboratory scientists, require an appropriate patient base, and incorporate laboratory and immunologic endpoints in addition to standard clinical endpoints. The clinical research program will be directed towards three major objectives: 1. developing and testing immunotherapeutic approaches for Prostate Cancer; 2. continue to study Melanoma biology and develop novel therapeutic approaches to this disease. Therapies to be tested may extend beyond solely immune-based approaches and will include active participation at all levels (institutional, multi-institutional, and large cooperative group) of trial design and implementation; and 3. continue efforts to make the Cytokine Working Group (CWG) an NCI funded cooperative group in Tumor Immunotherapy by becoming a mechanism to rapidly and creatively test more complex immune oriented approaches primarily in phase II trials. The mentoring of beginning clinical investigators is a critical component of the K24 and will be focused on bringing junior faculty and/or Hematology/Oncology fellows into one of several areas of training with well defined responsibilities and educational programs. These include: 1. the Tumor Immunotherapy Program emphasizing pre-clinical, laboratory work, incorporation of immune monitoring into clinical trial design, and protocol preparation and implementation; 2. Genitourinary (GU) Cancer Multidisciplinary Program with an emphasis on prostate immunotherapy; and 3. As the Director of Clinical Research within the Section of Hematology/Oncology provide an introduction to clinical trials research including an overview of faculty expertise and how to initiate clinical investigation with one of the faculty. Furthermore, I will act as a consultant for their clinical research. By combining my efforts to merge laboratory efforts and immunologic endpoints with strong clinical trial design, I believe clinical research can better move tumor immunotherapy forward in a more rationale way.